Novartis Ag (NVS) Assets (2009 - 2025)
Novartis Ag's (NVS) quarterly Assets came in at $110.9 billion in Q4 2025, up 8.51% year-on-year from $102.2 billion in Q4 2024, and up 6.28% quarter-over-quarter from $104.4 billion in Q2 2025.
Novartis Ag (NVS) Assets (2009 - 2025) Analysis & Trends
Novartis Ag has disclosed Assets across 12 years of filings, most recently posting $110.9 billion for Q4 2025.
- Assets for Q4 2025 came in at $110.9 billion, up 8.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $110.9 billion (up 8.51% YoY), and the FY2025 annual result was $110.9 billion, up 8.51% from the prior year.
- Assets came in at $110.9 billion for Q4 2025 at Novartis Ag, up from $104.4 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $131.8 billion in Q4 2021 to a low of $97.5 billion in Q2 2024.
- The 5-year median for Assets is $111.0 billion (2023), against an average of $112.2 billion.
- Across the five-year window, Assets fell 14.91% in 2023 and gained 8.51% in 2025, its largest moves.
- Novartis Ag's Assets stood at $131.8 billion in 2021, then declined by 10.88% to $117.5 billion in 2022, then declined by 14.91% to $99.9 billion in 2023, then advanced by 2.3% to $102.2 billion in 2024, then rose by 8.51% to $110.9 billion in 2025.
- The last three Assets figures came in at $110.9 billion (Q4 2025), $104.4 billion (Q2 2025), and $102.2 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 84.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.95 Bn |
| Jun 30, 2025 | 104.40 Bn |
| Dec 31, 2024 | 102.25 Bn |
| Jun 30, 2024 | 97.51 Bn |
| Dec 31, 2023 | 99.95 Bn |
| Jun 30, 2023 | 110.98 Bn |
| Dec 31, 2022 | 117.45 Bn |
| Jun 30, 2022 | 122.91 Bn |
| Dec 31, 2021 | 131.80 Bn |
| Jun 30, 2021 | 124.02 Bn |
| Dec 31, 2020 | 127.78 Bn |
| Jun 30, 2020 | 123.76 Bn |
| Dec 31, 2019 | 118.37 Bn |
| Jun 30, 2019 | 116.29 Bn |
| Dec 31, 2018 | 145.56 Bn |
| Jun 30, 2018 | 142.06 Bn |
| Dec 31, 2017 | 133.08 Bn |
| Dec 31, 2016 | 130.12 Bn |
| Mar 31, 2010 | 95,795,000.00 Bn |
| Dec 31, 2009 | 95,505,000.00 Bn |